Answer to Question 1
C
Sumatriptan, other triptans, and ergot alkaloids all cause vasoconstriction and should not be combined, or excessive and prolonged vasospasm could result. Sumatriptan should not be used within 24 hours of an ergot derivative and another triptan. A family history is important, but it is not vital assessment data as it relates to this scenario. Acetaminophen has no drug-to-drug inte-raction with sumatriptan. Sulfa is not a component of sumatriptan and therefore is not relevant.
Answer to Question 2
C
Because metoprolol may mask the signs of hypoglycemia, the patient should monitor the blood glucose closely and report changes to the prescriber. Metoprolol does have an indirect effect on diabetes mellitus and/or insulin requirements in that it may mask the signs of hypoglycemia, causing the patient to make a healthcare decision based on the drug-to-drug interaction rather than actual physiologic factors. The patient should not increase the insulin, because metoprolol will cause a decrease in blood glucose, increasing the risk of a hypoglycemic reaction. The patient should not reduce the dose of insulin when taking metoprolol, because this might alter serum glucose levels.
Subcutaneous drug administration: (a) cross section of skin showing depth of needle insertion;
PET Scans of a Patient with Parkinsonian Symptoms
ROM exercises on a patient’s wrist: ulnar deviation.
Drug Administration Guidelines with Enteral Feedings
Ex vivo and in vivo gene therapy for a patient with a liver disorder
Round your answer to the nearest tenth. A patient with a pulmonary embolus has Refludan ...